Cancer Rates Drop After Age 85: Stanford Study Reveals Why Aging Protects Against Tumors

Growing old isn’t always fun, but research suggests it may ward off cancer.

A curious pattern in cancer statistics has puzzled scientists for decades. While cancer risk climbs steadily through middle age and beyond, it levels off and even declines among the oldest populations. A Stanford University study using genetically engineered mice now offers a potential explanation. Aging itself may actively suppress tumor growth.

Research published in Nature Aging shows that despite accumulating more cancer-causing mutations throughout life, very old bodies appear to develop mechanisms that prevent those mutations from sparking tumor growth. In experiments comparing young adult mice to aged mice, the older animals developed dramatically fewer and smaller lung tumors when given identical cancer-driving mutations.

While cancer rates rise through most of adulthood, they flatten and can even decline in people over 85. This Stanford mouse study reveals that aging tissues may actively resist tumor growth, even as mutations accumulate. This suggests the elderly have natural defenses that counteract cancer development.

Older Mice Showed Dramatic Resistance to Tumor Growth

The Stanford team, led by Emily G. Shuldiner, Dmitri A. Petrov, and Monte M. Winslow, initiated lung tumors in mice using the same KRAS gene mutation, one of the most common cancer drivers in humans. Young mice were 4-6 months old (roughly equivalent to early human adulthood), while aged mice were 20-21 months old (corresponding to an age when most molecular hallmarks of aging have emerged in mice).

The difference was stark. Aged mice had tumor burdens two to three times lower than young mice. When researchers used molecular barcoding to track individual tumors, they found aging reduced both the number of tumors that formed and how large each tumor grew. Tumors in aged mice were consistently smaller across the entire size distribution.

How Aging Weakens Cancer-Driving Mutations

To understand what creates this age-related resistance, the team examined how aging affects tumor suppressor genes—the molecular brakes that normally prevent uncontrolled cell growth. Using a genetic screening approach, they tested 25 different tumor suppressors simultaneously in young and aged mice.

While tumor suppressor genes generally retained their protective functions in aged mice, aging weakened the advantage that tumors gained from inactivating many of these genes. Mutations that would normally supercharge tumor growth in young mice provided less benefit in aged animals.

One gene showed particularly pronounced age-dependent effects: PTEN, a master regulator of the PI3K-AKT pathway that controls cell growth and survival. In young mice, losing PTEN function caused tumors to explode in size. In aged mice, PTEN inactivation had roughly half the impact. Researchers validated this finding across multiple independent experiments using different genetic tools, confirming it wasn’t a technical artifact.

Molecular Analysis Reveals How Aging Persists in Cancer Cells

The team performed single-cell RNA sequencing on nearly 180,000 cells from tumor-bearing lungs to understand the molecular basis of these effects. Cancer cells from aged mice maintained age-related changes in gene expression even after becoming cancerous—the cellular signatures of aging weren’t erased by transformation.

Aged cancer cells showed reduced activity in the MAPK signaling pathway, which normally drives cell division downstream of cancer-causing KRAS mutations. Aging appears to rewire how cancer-promoting signals function inside cells.

When PTEN was inactivated in aged mice, it partially reversed molecular signatures of aging in both cancer cells and surrounding tissues. Tumors and their microenvironments in aged PTEN-deficient mice looked transcriptionally “younger” than tumors in aged mice with normal PTEN. This finding reveals deep connections between the molecular pathways controlling aging and cancer.

Testing Alternative Explanations

The research addressed several alternative explanations for the age-related cancer resistance. Cellular senescence—a state where cells stop dividing that’s often considered protective against cancer—didn’t appear to be the primary mechanism. When the team inactivated genes that drive senescence, including p53 and Cdkn2a, these changes weren’t more protective in aged mice as would be expected if senescence were the main driver.

The team also tested whether aging of the immune system might explain the results by targeting genes involved in antigen presentation and interferon signaling. Inactivating most of these genes had minimal effects on tumor growth in either young or aged mice, suggesting immune aging through these pathways wasn’t responsible for the age-related differences.

When researchers repeated experiments in mice lacking p53, they saw similar patterns. Aging broadly dampened the effects of tumor suppressor loss, and PTEN inactivation again showed the most dramatic age-dependent reduction in impact.

Implications for Human Cancer

In humans, cancer incidence rates rise exponentially through most of adulthood before the curve flattens and eventually declines in people over 85. This pattern remains controversial, with some researchers attributing it to reduced diagnostic intensity in the elderly or statistical artifacts. The new mouse study supports a biological explanation.

The findings raise questions about cancer prevention and treatment in older patients. If aging creates tissue environments that naturally suppress tumor growth, understanding these mechanisms could inspire new approaches. The research also suggests that the molecular state of aging may need to be considered when designing cancer treatments, since the same genetic changes may have different effects depending on a patient’s age.

The research provides a framework for understanding why cancer incidence doesn’t continue climbing indefinitely with age. While elderly individuals have accumulated more mutations over their lifetimes, their tissues may have also developed robust tumor-suppressive changes that counteract those mutations. This balance between pro-cancer mutation accumulation and anti-cancer tissue aging may explain the deceleration in cancer rates among the oldest old—and could point toward new strategies for cancer prevention that harness the body’s age-related defenses.

---